These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10851834)

  • 1. Reversibility of acute demyelinating lesions in relapsing-remitting multiple sclerosis.
    Khan OA; Rothman MI
    J Pak Med Assoc; 2000 Apr; 50(4):128-30. PubMed ID: 10851834
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
    J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relapsing-remitting inflammatory disease of the central nervous system with normal MRI: multiple sclerosis or phenocopy in a series of 15 patients].
    Lebrun C; Bourg V; Chanalet S; Chatel M
    Rev Neurol (Paris); 2003 Apr; 159(4):397-404. PubMed ID: 12773868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
    BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of relapsing-remitting tumour-like inflammation of the central nervous system.
    Miante S; Perini P; Rinaldi F; Gallo P
    Mult Scler; 2015 Nov; 21(13):1742-5. PubMed ID: 26362889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome.
    Khalil M; Enzinger C; Langkammer C; Petrovic K; Loitfelder M; Tscherner M; Jehna M; Bachmaier G; Wallner-Blazek M; Ropele S; Schmidt R; Fuchs S; Fazekas F
    Mult Scler; 2011 Feb; 17(2):173-80. PubMed ID: 20956399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous intracerebral hemorrhage in a patient with multiple sclerosis and tumefactive demyelinating lesion.
    Stich O; Janowitz D; Rauer S
    Mult Scler; 2009 Apr; 15(4):517-9. PubMed ID: 19282415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsing-remitting tumefactive demyelination.
    Brandão E; Melo-Pires M; Veira C
    JAMA Neurol; 2014 Mar; 71(3):366-7. PubMed ID: 24445489
    [No Abstract]   [Full Text] [Related]  

  • 11. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.
    Berger JR
    Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report.
    Navardi S; Sahraian MA; Naser Moghadasi A
    Rev Neurol (Paris); 2020 May; 176(4):289-290. PubMed ID: 31668286
    [No Abstract]   [Full Text] [Related]  

  • 13. Barkhof magnetic resonance imaging criteria predict early relapse in pediatric multiple sclerosis.
    Neuteboom RF; Ketelslegers IA; Boon M; Catsman-Berrevoets CE; Hintzen RQ;
    Pediatr Neurol; 2010 Jan; 42(1):53-5. PubMed ID: 20004863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.
    Börnsen L; Khademi M; Olsson T; Sørensen PS; Sellebjerg F
    Mult Scler; 2011 Jan; 17(1):32-42. PubMed ID: 20921238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse.
    Li XL; Zhang ZC; Zhang B; Jiang H; Yu CM; Zhang WJ; Yan X; Wang MX
    Int Immunopharmacol; 2014 Dec; 23(2):546-9. PubMed ID: 25448497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.
    Créange A; Debouverie M; Jaillon-Rivière V; Taithe F; Liban D; Moutereau A; Clavelou P; Defer G
    Mult Scler; 2009 Sep; 15(9):1085-91. PubMed ID: 19556312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.
    Acaster S; Swinburn P; Wang C; Stemper B; Beckmann K; Knappertz V; Pohl C; Sandbrink R; Gondek K; Edan G; Kappos L; Freedman M; Hartung HP; Arnason B; Comi G; Filippi M; Jeffery D; O'Connor P; Cook S; Lloyd AJ
    Mult Scler; 2011 Dec; 17(12):1504-13. PubMed ID: 21757536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [2012: Update on diagnosis and treatment of multiple sclerosis].
    Havla J; Kümpfel T; Hohlfeld R
    Dtsch Med Wochenschr; 2012 Apr; 137(17):894-9. PubMed ID: 22492476
    [No Abstract]   [Full Text] [Related]  

  • 19. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
    Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis.
    Kincses ZT; Ropele S; Jenkinson M; Khalil M; Petrovic K; Loitfelder M; Langkammer C; Aspeck E; Wallner-Blazek M; Fuchs S; Jehna M; Schmidt R; Vécsei L; Fazekas F; Enzinger C
    Mult Scler; 2011 Jun; 17(6):681-9. PubMed ID: 21177325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.